Obesity and Pulmonary Hypertension: A Contemporary Review
Authors:
- Jyoti JainJJJyoti Jain
- Rahul KarnaRKRahul Karna
- Tanveer Ud Din MianTMTanveer Ud Din Mian
- Adeel NasrullahANAdeel Nasrullah
- Palash AsawaPAPalash Asawa
- Laith AlhuneafatLALaith Alhuneafat
- Pushan AggarwalPAPushan Aggarwal
- Amresh RainaARAmresh Raina
- Briana DiSilvioBDBriana DiSilvio
- Hayah Kassis-GeorgeHKHayah Kassis-George
Open Access
- 14 November 2026
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (22) , 8934
Abstract
Obesity and pulmonary hypertension (PH) frequently coexist, but obesity is not a distinct PH group. This narrative review of the literature published through 27 September 2026 appraises the evidence by PH group. Obesity is most clearly linked to PH through intermediate conditions, particularly heart failure with preserved ejection fraction, obstructive sleep apnea, and obesity hypoventilation syndrome, and it can complicate hemodynamic classification because elevated intrathoracic pressure may raise the measured pulmonary arterial wedge pressure. Experimental studies suggest direct pulmonary vascular effects through adipokine imbalance, inflammation, altered estrogen metabolism, oxidative stress, and insulin resistance; however, an independent causal role of obesity in human pulmonary arterial hypertension has not been established. Small, mostly observational studies report lower estimated pulmonary pressures after bariatric surgery, but a benefit of intentional weight loss on invasive hemodynamics or clinical PH outcomes is unproven. Incretin-based therapies produce substantial weight loss and improve symptoms in obesity-related heart failure with preserved ejection fraction; acute human hemodynamic data are emerging, but long-term efficacy in PH has not been tested. Higher body mass index has been associated with lower observed mortality in several PH cohorts, possibly reflecting confounding and reverse causation. We distinguish established findings from hypotheses and highlight research priorities.Keywords
This publication has 95 references indexed in Scilit:
- GLP-1 Receptor Agonists in Pulmonary Hypertension: Mechanistic Rationale, Preclinical Evidence, and Clinical Knowledge GapsLung, 2026
- Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or ObesityJAMA Internal Medicine, 2024
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or ObesityJAMA, 2021
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or ObesityJAMA, 2021
- Improvement in severe pulmonary hypertension in obese patients after laparoscopic gastric bypass or sleeve gastrectomySurgical Endoscopy, 2015
- Adiponectin Levels Are Elevated in Patients With Pulmonary Arterial HypertensionClinical Cardiology, 2013
- Reactive Oxygen Species in Pulmonary Vascular Remodeling2013
- Overweight, Obesity, and the Risk of Recurrent Venous ThromboembolismArchives of internal medicine (1960), 2008
- The correlation between adiposity and adiponectin, tumor necrosis factor α, interleukin-6 and high sensitivity C-reactive protein levels. Is adipocyte size associated with inflammation in adults?Journal of Endocrinological Investigation, 2007
- Paradoxical Decrease of an Adipose-Specific Protein, Adiponectin, in ObesityBiochemical and Biophysical Research Communications, 1999